A trial assessing clopidogrel’s effectiveness in preventing ischaemic complications in high-risk* patients receiving standard cardiopreventive therapy—e.g., aspirin.
*Previously documented cardiovascular, neurovascular, or peripheral arterial manifestations of atherothrombosis; and combinations of recognized risk factors for atherosclerosis.
Primary endpoint Any event of a composite endpoint–nonfatal MI or stroke or cardiovascular death.
Conclusion Clopidogrel plus aspirin wasn’t more effective than aspirin alone in reducing myocardial infarction, stroke, or cardiovascular death.
Abbreviation for Clopidogrel for High Atherothrombotic Risk & Ischemic Stabilization, Management & Avoidance
Reference N Engl J Med 2006; 354:1706-1717April 20, 2006